DailyMed
Cure8 regulatory brief
DailyMed label update for INFLECTRA
Medications
Infliximab
Anti-TNF
Biosimilars
Immunomodulators
Regulatory Update
Adult patients
Pediatric Patients
Why This Matters
Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label highlights infection and malignancy risks and pediatric approvals that may change treatment conversations.
Patients already receiving or considering INFLECTRA may need to discuss screening, monitoring, and concomitant immunomodulator use with their care team.
Who Should Pay Attention
Adult and pediatric patients with Crohn’s disease or ulcerative colitis; patients on or considering anti-TNF biologics/biosimilars; clinicians and infusion centers; pharmacists and payers.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Source depthMetadata only
What To Know
This DailyMed entry is a prescribing information (label) update for INFLECTRA (infliximab-dyyb), a biosimilar to Remicade.
The highlights include boxed warnings, approved indications (including adult and pediatric Crohn’s disease and ulcerative colitis), dosing schedules, administration details (intravenous infusion), dosage forms, contraindications, and safety warnings such as serious infections and malignancy risks.
What changed and will be clear in the label text; patients on or considering infliximab should review the updated warnings, dosing guidance, and pediatric indications with their clinicians.
Clinicians will find the full prescribing information necessary for clinical decisions, including recommended screening for latent TB and monitoring for infections and malignancy. The label also references risks when combined with azathioprine or 6-mercaptopurine (HSTCL risk) and provides infusion administration precautions.
For practical questions about access, dosing changes, or insurance coverage for the biosimilar, contact your prescribing clinician or pharmacist.
Keep In Mind
This is the official prescribing information (DailyMed) for a US-approved biosimilar (infliximab-dyyb). Label text is comprehensive but written for clinicians; discuss individual treatment decisions with your healthcare provider. The label includes boxed warnings and safety monitoring recommendations; it does not itself provide individualized medical advice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationDailyMed
Study typeDrug Label Update
Indexed viaDailyMed
Source typeDrug label record
PublishedJul 28, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.
Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...
Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.
Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...